Language
English
Publication Date
8-1-2024
Journal
Clinical Gastroenterology and Hepatology
DOI
10.1016/j.cgh.2024.01.032
PMID
38367743
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1 in 3-4 adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (2 in 3) and MASH with fibrosis (1 in 5) in adults with obesity and diabetes. This review summarizes the role of glucagon-like peptide-1 receptor agonists in treating MASLD/MASH. Although not approved by the Food and Drug Administration for the treatment of MASLD, this class of medication is available to treat obesity and type 2 diabetes and has been shown to reverse steatohepatitis, reduce cardiovascular risk, and is safe to use across the spectrum of MASLD with or without fibrosis.
Keywords
Humans, Fatty Liver, Diabetes Mellitus, Type 2, Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Cirrhosis, GLP-1, Metabolic Dysfunction-Associated Steatotic Liver Disease, Steatosis
Published Open-Access
yes
Recommended Citation
Abushamat, Layla A; Shah, Pir Ahmad; Eckel, Robert H; et al., "The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis" (2024). Faculty and Staff Publications. 4234.
https://digitalcommons.library.tmc.edu/baylor_docs/4234
Graphical Abstract